Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on heal...
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion ...
https://www.reuters.com/world/novo-nordisk-begins-round-layoffs-united-states-sources-say-2025-10-15/
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rar...
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and raises the price target...
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservatio...
https://scholarrock.com/our-company/newsroom/update-on-third-party-manufacturing-site/
